[Immunotherapy of pulmonary tuberculosis].
Khudzik. L B LB; Salina. T Iu TIu; Parolina. L E LE
Key Findings
- Thymalin, thymogen, and interferon were tested as immune‑correctors in TB patients
- The thymogen‑plus‑interferon combo gave the strongest early improvement
- Benefits grew once lung fibrosis healed, yet significant residual lung changes remained
Practical Outcomes
- For biohackers, the data shows thymogen with interferon can enhance immune response in a specific disease setting, but it doesn’t translate into a clear, safe protocol for general health or longevity. No dosing details are provided, and the study is limited to TB, so it’s not a ready‑to‑use regimen for most people.
Summary
In a study of 553 people with severe lung TB, doctors tried immune‑boosting drugs called thymalin, thymogen, and interferon, alone or together. The combo of thymogen plus interferon worked best early on, especially after the scar tissue in the lungs started to heal, but patients still ended up with noticeable lung damage.
Abstract
The efficiency of treating patients with destructive tuberculosis by using different immune correctors was comparatively analyzed. Five hundred and fifty three patients were treated with thymalin, thymogen, human leukocytic interferon, and a combination of thymogen and interferon. The benefit from immunocorrector treatment was obtained early in the complex therapy and the best result was achieved by the use of thymogen plus interferon. However, the action of the two immunocorrectors increased when fibrous deformity of the lung was healed, followed by the development of pronounced residual changes.
Study Information
pubmed
1998